June 11 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* MESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN
* MESOBLAST LTD - EXPANDED ITS PARTNERSHIP WITH JCR PHARMACEUTICALS CO. LTD. IN JAPAN
* MESOBLAST LTD - DEAL FOR USE OF MESENCHYMAL STEM CELLS (MSCS) FOR TREATMENT OF NEWBORNS WHO LACK SUFFICIENT BLOOD SUPPLY AND OXYGEN TO BRAIN
* MESOBLAST LTD - DEAL FOR AGREEMENT HAS NOW BEEN FURTHER EXPANDED TO PROVIDE JCR WITH RIGHTS TO SELL TEMCELL FOR HIE
* MESOBLAST LTD - DEAL FOR JCR PLANS TO INITIATE A CLINICAL TRIAL OF TEMCELL IN NEWBORNS WITH HIE IN JULY 2019